Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 19/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.62 |
| ▸ | ITGA5 | P08648 | 4/20 | 0.62 |
| ▸ | ITGB1 | P05556 | 3/20 | 0.62 |
| ▸ | ITGB6 | P18564 | 13/20 | 0.53 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19953675 | 1.00 | ITGAV (0.62) | ITGAVITGB3ITGA5ITGB1ITGB6 | |
| SCHEMBL20025187 | 0.94 | ITGAV (0.62) | ITGAVITGB3ITGA5ITGB1ITGB6 | |
| SCHEMBL30449533 | 0.94 | ITGAV (0.62) | ITGAVITGB3ITGA5ITGB1ITGB6 | |
| SCHEMBL20024876 | 0.94 | ITGAV (0.62) | ITGAVITGB3ITGA5ITGB1ITGB6 | |
| SCHEMBL19953598 | 0.86 | ITGAV (0.73) | ITGAVITGB3ITGA5ITGB1ITGB6 | |
| SCHEMBL19953599 | 0.86 | ITGAV (0.73) | ITGAVITGB3ITGA5ITGB1ITGB6 | |
| SCHEMBL19953674 | 0.86 | ITGAV (0.65) | ITGAVITGB3ITGA5ITGB1ITGB6 | |
| SCHEMBL19953673 | 0.86 | ITGAV (0.65) | ITGAVITGB3ITGA5ITGB1ITGB6 | |
| SCHEMBL30449468 | 0.86 | ITGAV (0.65) | ITGAVITGB3ITGA5ITGB1ITGB6 | |
| SCHEMBL21812281 | 0.86 | ITGAV (0.70) | ITGAVITGB3ITGA5ITGB1ITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10604520-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | claimed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20210024516-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-20210024516-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| US-10604520-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-10604520-B2 | N-acyl amino acid compounds and methods of use | PLIANT THERAPEUTICS, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| EP-3509590-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | Pliant Therapeutics, Inc. (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20180093984-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| US-20180093984-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2018-04-05 | — | — | US | disclosed |
| WO-2018049068-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604520-B2 | N-acyl amino acid compounds and methods of use | ITGA1, ITGB1, ITGAL | ITGAV 4/4885ITGB3 9/4885ITGA5 6/4885 |
| US-11673887-B2 | N-acyl amino acid compounds and methods of use | ITGA1, ITGB1, ITGAL | ITGAV 4/4885ITGB3 9/4885ITGA5 6/4885 |
| US-20210024516-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | ITGAV 4/4885ITGB3 9/4885ITGA5 6/4885 |
| US-20230365556-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | ITGAV 4/4885ITGB3 9/4885ITGA5 6/4885 |
| US-20180093984-A1 | N-ACYL AMINO ACID COMPOUNDS AND METHODS OF USE | ITGA1, ITGB1, ITGAL | ITGAV 4/4885ITGB3 9/4885ITGA5 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.